Form 8-K - Current report:
SEC Accession No. 0001420720-23-000041
Filing Date
2023-09-21
Accepted
2023-09-21 08:00:54
Documents
18
Period of Report
2023-09-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20230915x8k.htm   iXBRL 8-K 54738
2 EX-10.1 ibio-20230915xex10d1.htm EX-10.1 309415
3 EX-10.2 ibio-20230915xex10d2.htm EX-10.2 59172
4 EX-99.1 ibio-20230915xex99d1.htm EX-99.1 398724
5 GRAPHIC ibio-20230915xex10d1001.jpg GRAPHIC 40074
  Complete submission text file 0001420720-23-000041.txt   1181459

Data Files

Seq Description Document Type Size
6 EX-101.SCH ibio-20230915.xsd EX-101.SCH 4184
7 EX-101.DEF ibio-20230915_def.xml EX-101.DEF 3258
8 EX-101.LAB ibio-20230915_lab.xml EX-101.LAB 674
9 EX-101.PRE ibio-20230915_pre.xml EX-101.PRE 10593
12 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20230915x8k_htm.xml XML 4621
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 231267771
SIC: 2834 Pharmaceutical Preparations